Intermittent hypoxia and activation of inflammatory molecular pathways in OSAS

Archives of Physiology and Biochemistry

Volumn 114, Issue 4, 2008, Pages 261-266

  Ryan, Silke ^b   McNicholas, Walter T ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b NONE

Author keywords

Cardiovascular disease; Inflammation; Intermittent hypoxia; Obstructive sleep apnoea syndrome

Indexed keywords

CYTOKINE;

ANIMAL; ANOXIA; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASE; CELL ADHESION; HUMAN; INFLAMMATION; LYMPHOCYTE; METABOLISM; MONOCYTE; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; SLEEP APNEA SYNDROME;

ANIMALS; ANOXIA; CARDIOVASCULAR DISEASES; CELL ADHESION; CYTOKINES; HUMANS; INFLAMMATION; LYMPHOCYTES; MODELS, BIOLOGICAL; MONOCYTES; OBESITY; SLEEP APNEA, OBSTRUCTIVE;

EID: 54349109849     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.1080/13813450802307337     Document Type: Review

References (62)

1. Akashiba T, Akahoshi T, Kawahara S, Majima T, Horie T. 2005. Effects of long-term nasal continuous positive airway pressure on C-reactive protein in patients with obstructive sleep apnea syndrome. Intern Med 44:899-900.
2. Alam I, Lewis K, Stephens JW, Baxter JN. 2007. Obesity, metabolic syndrome and sleep apnoea: all pro-inflammatory states. Obes Rev 8:119-27.
3. Alzoghaibi MA, Bahammam AS. 2005. Lipid peroxides, superoxide dismutase and circulating IL-8 and GCP-2 in patients with severe obstructive sleep apnea: a pilot study. Sleep Breath 9:119-26.
4. Barcelo A, Barbe F, Llompart E, Mayoralas LR, Ladaria A, Bosch M, Agusti AG. 2004. Effects of obesity on C-reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea. Am J Med 117:118-21.
5. Bonizzi G, Karin M. 2004. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25:280-88.
6. Can M, Acikgoz S, Mungan G, Bayraktaroglu T, Kocak E, Guven B, Demirtas S. 2006. Serum cardiovascular risk factors in obstructive sleep apnea. Chest 129:233-7.
7. Cao JJ, Arnold AM, Manolio TA, Polak JF, Psaty BM, Hirsch CH, Kuller LH, Cushman M. 2007. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation 116:32-8.
8. Ciftci TU, Kokturk O, Bukan N, Bilgihan A. 2004. The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome. Cytokine 28:87-91.
9. Cook SA, Sugden PH, Clerk A. 1999. Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease. J Mol Cell Cardiol 31:1429-34.
10. Cummins EP, Taylor CT. 2005. Hypoxia-responsive transcription factors. Pflugers Arch 450:363-71.
11. Doherty LS, Kiely JL, Swan V, McNicholas WT. 2005. Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. Chest 127:2076-84.
12. Dyugovskaya L, Lavie P, Lavie L. 2002. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 165:934-9.
13. Dyugovskaya L, Lavie P, Lavie L. 2003. Phenotypic and functional characterization of blood gammadelta T cells in sleep apnea. Am J Respir Crit Care Med 168:242-9.
14. Dyugovskaya L, Lavie P, Lavie L. 2005. Lymphocyte activation as a possible measure of atherosclerotic risk in patients with sleep apnea. Ann NY Acad Sci 1051:340-50.
15. El-Solh AA, Mador MJ, Sikka P, Dhillon RS, Amsterdam D, Grant BJ. 2002. Adhesion molecules in patients with coronary artery disease and moderate-to-severe obstructive sleep apnea. Chest 121:1541-7.
16. Engleman HM, Douglas NJ. 2004. Sleep 4: Sleepiness, cognitive function, and quality of life in obstructive sleep apnoea/ hypopnoea syndrome. Thorax 59:618-22.
17. Fantuzzi G. 2005. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115:911-19; quiz 920.
18. Glass CK, Witztum JL. 2001. Atherosclerosis the road ahead. Cell 104:503-16.
19. Greenberg H, Ye X, Wilson D, Htoo AK, Hendersen T, Liu SF. 2006. Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem Biophys Res Commun 343:591-6.
20. Guilleminault C, Kirisoglu C, Ohayon MM. 2004. C-reactive protein and sleep-disordered breathing. Sleep 27:1507-11.
21. Guilleminault C, Tilkian A, Dement WC. 1976. The sleep apnea syndromes. Annu Rev Med 27:465-84.
22. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. 1997. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349:462-6.
23. Hayakawa M, Miyashita H, Sakamoto I, Kitagawa M, Tanaka H, Yasuda H, Karin M, Kikugawa K. 2003. Evidence that reactive oxygen species do not mediate NF-kappaB activation. Embo J 22:3356-66.
24. Khera A, de Lemos JA, Peshock RM, Lo HS, Stanek HG, Murphy SA, Wians FH Jr, Grundy SM, McGuire DK. 2006. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation 113:38-43.
25. Kiely JL, McNicholas WT. 2000. Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome. Eur Respir J 16:128-33.
26. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, Gaestel M. 1999. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1:94-97.
27. Lavie L. 2003. Obstructive sleep apnoea syndrome-an oxidative stress disorder. Sleep Med Rev 7:35-51.
28. M, Georgakopoulos D, Lu G, Hester L, Kass DA, Hasday J, Wang Y. 2005. p38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart. Circulation 111:2494-502.
29. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. 1994. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331:417-24.
30. Marin JM, Carrizo SJ, Vicente E, Agusti AG. 2005. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365:1046-53.
31. McNicholas WT, Bonsigore MR. 2007. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 29:156-78.
32. Mehra R, Storfer-Isser A, Kirchner HL, Johnson N, Jenny N, Tracy RP, Redline, S. 2006. Soluble interleukin 6 receptor: A novel marker of moderate to severe sleep-related breathing disorder. Arch Intern Med 166:1725-31.
33. Miller M, Zhan M, Havas S. 2005. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med 165:2063-68.
34. Minoguchi K, Tazaki T, Yokoe T, Minoguchi H, Watanabe Y, Yamamoto M, Adachi M. 2004. Elevated production of tumor necrosis factor-alpha by monocytes in patients with obstructive sleep apnea syndrome. Chest 126:1473-79.
35. Nacher M, Serrano-Mollar A, Farre R, Panes J, Segui, J Montserrat JM. 2007. Recurrent obstructive apneas trigger early systemic inflammation in a rat model of sleep apnea. Respir Physiol Neurobiol 155:93-6.
36. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, D'Agostino RB, Newman AB, Lebowitz MD, Pickering TG. 2000. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. Jama 283:1829-36.
37. Ohga E, Tomita T, Wada H, Yamamoto H, Nagase T, Ouchi Y. 2003. Effects of obstructive sleep apnea on circulating ICAM-1, IL-8, and MCP-1. J Appl Physiol 94:179-84.
38. Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J. 2002. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. Am J Respir Crit Care Med 166:159-65.
39. Peppard PE, Young T, Palta M, Skatrud J. 2000. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 342:1378-84.
40. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. 1998. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731-3.
41. Ryan S, McNicholas WT, Taylor CT. 2007a. A critical role for p38 map kinase in NF-kappaB signaling during intermittent hypoxia/reoxygenation. Biochem Biophys Res Commun 355:28-733.
42. Ryan S, Nolan GM, Hannigan E, Cunningham S, Taylor C, McNicholas WT. 2007b. Cardiovascular risk markers in obstructive sleep apnoea syndrome and correlation with obesity. Thorax 62:509-14.
43. Ryan S, Taylor CT, McNicholas WT. 2005. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 112:2660-67.
44. Ryan S, Taylor CT, McNicholas WT. 2006. Predictors of elevated nuclear factor-kappaB-dependent genes in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 174:824-30.
45. Saletu M, Nosiska D, Kapfhammer G, Lalouschek W, Saletu B, Benesch T, Zeitlhofer J. 2006. Structural and serum surrogate markers of cerebrovascular disease in obstructive sleep apnea (OSA). Association of mild OSA with early atherosclerosis. J Neurol 253:746-52.
46. Schulz R, Mahmoudi S, Hattar K, Sibelius U, Olschewski H, Mayer K, Seeger W, Grimminger F. 2000. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 162:566-70.
47. Semenza GL. 2004. O2-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-1. J Appl Physiol 96:1173-7; discussion 1170-72.
48. Shamsuzzaman AS, Winnicki M, Lanfranchi P, Wolk R, Kara T, Accurso V Somers VK. 2002. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 105:2462-4.
49. Steiropoulos P, Tsara V, Nena E, Fitili C, Kataropoulou M, Froudarakis M, Christaki P, Bouros D. 2007. Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome. Chest 132:843-51.
50. Stoohs RA, Bingham LA, Itoi A, Guilleminault C, Dement WC. 1995. Sleep and sleep-disordered breathing in commercial long-haul truck drivers. Chest 107:1275-82.
51. Sullivan CE, Issa FG, Berthon-Jones M, Eves L. 1981. Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet 1:862-5.
52. Taheri S, Austin D, Lin L, Nieto FJ, Young T, Mignot E. 2007. Correlates of serum C-reactive protein (CRP)-no association with sleep duration or sleep disordered breathing. Sleep 30:991-6.
53. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. 1997. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 82:1313-16.
54. Vgontzas AN, Zoumakis E, Lin HM, Bixler EO, Trakada G, Chrousos GP. 2004. Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-alpha antagonist. J Clin Endocrinol Metab 89:4409-13.
55. Willerson JT, Ridker PM. 2004. Inflammation as a cardiovascular risk factor. Circulation 109:II2-10.
56. Yamauchi M, Tamaki S, Tomoda K, Yoshikawa M, Fukuoka A, Makinodan K, Koyama N, Suzuki T Kimura H. 2006. Evidence for activation of nuclear factor kappaB in obstructive sleep apnea. Sleep Breath 10:189-93.
57. Yao M, Tachibana N, Okura M, Ikeda A, Tanigawa T, Yamagishi K, Sato S, Shimamoto T, Iso H. 2006. The relationship between sleep-disordered breathing and high-sensitivity C-reactive protein in Japanese men. Sleep 29:661-5.
58. Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G, Hirano T, Adachi M. 2003. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 107:1129-34.
59. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. 1993. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328:1230-35.
60. Young T, Peppard P, Palta M, Hla KM, Finn L, Morgan B, Skatrud J. 1997. Population-based study of sleep-disordered breathing as a risk factor for hypertension. Arch Intern Med 157:1746-52.
61. Yuan G, Nanduri J, Bhasker CR, Semenza GL, Prabhakar NR. 2005. Ca2+/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J Biol Chem 280:4321-8.
62. Zarubin T, Han J. 2005. Activation and signaling of the p38 MAP kinase pathway. Cell Res 15:11-18.